

Cambridge University Press  
978-0-521-74399-0 - The Prescriber's Guide, Third Edition  
Stephen M. Stahl  
Frontmatter  
[More information](#)



# Stahl's Essential Psychopharmacology

## The Prescriber's Guide

### THIRD EDITION

This completely revised and updated edition of Stephen M. Stahl's much-acclaimed *Prescriber's Guide* is the latest addition to the Essential Psychopharmacology range. Seven new drugs have been added, and every drug has been revised and updated to take into account new regulations and uses.

In full color throughout, and with four or more pages for each of the more than 100 psychotropic drugs, Stephen M. Stahl distills his great expertise into a pragmatic formulary that gives all the information a prescriber needs to treat patients effectively. Each drug is covered in five categories: general therapeutics, dosing and use, side effects, special populations, and pearls.

Target icons appear next to key categories for each drug so the prescriber can go easily and instantly to the information needed. Several indices are included, listing drugs by name (generic and international), use, and class. In addition, Dr. Stahl indicates which drugs have FDA approval and also gives the FDA Use-in-Pregnancy Ratings.

**Stephen M. Stahl** is Adjunct Professor of Psychiatry at the University of California at San Diego School of Medicine. He has conducted numerous research projects awarded by the National Institute of Mental Health, the Veterans Administration, and the pharmaceutical industry. The author of more than 300 articles and chapters, Stephen M. Stahl is an internationally recognized clinician, researcher, and teacher in psychiatry with subspecialty expertise in psychopharmacology.

Cambridge University Press  
978-0-521-74399-0 - The Prescriber's Guide, Third Edition  
Stephen M. Stahl  
Frontmatter  
[More information](#)



Stahl's Essential Psychopharmacology

---

**The Prescriber's  
Guide**  
THIRD EDITION

Stephen M. Stahl

University of California at San Diego,  
San Diego, California

Editorial assistant  
Meghan M. Grady

With illustrations by  
Nancy Muntner



**CAMBRIDGE**  
UNIVERSITY PRESS

Cambridge University Press  
978-0-521-74399-0 - The Prescriber's Guide, Third Edition  
Stephen M. Stahl  
Frontmatter  
[More information](#)

---

CAMBRIDGE UNIVERSITY PRESS  
Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, San Paulo, Delhi

CAMBRIDGE UNIVERSITY PRESS  
32 Avenue of the Americas, New York, NY 10013-2473, USA  
[www.cambridge.org](http://www.cambridge.org)

Information on this title: [www.cambridge.org/9780521743990](http://www.cambridge.org/9780521743990)

© Stephen M. Stahl 2009

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2009

Printed in the United States of America

*A catalog record for this publication is available from the British Library.*

*Library of Congress Cataloging in Publication Data*

ISBN 978-0-521-74399-0 paperback

Every effort has been made in preparing this book to provide accurate and up-to-date information that is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors, and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors, and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party Internet Web sites referred to in this publication and does not guarantee that any content on such Web sites is, or will remain, accurate or appropriate. Information regarding prices, travel timetables, and other factual information given in this work are correct at the time of first printing, but Cambridge University Press does not guarantee the accuracy of such information thereafter.

# Contents

Introduction	xi
List of icons	xiii
1. acamprosate	1
2. alprazolam	5
3. amisulpride	11
4. amitriptyline	17
5. amoxapine	25
6. amphetamine (d)	33
7. amphetamine (d,l)	39
8. aripiprazole	45
9. atomoxetine	51
10. bupropion	57
11. buspirone	63
12. carbamazepine	67
13. chlordiazepoxide	73
14. chlorpromazine	77
15. citalopram	83
16. clomipramine	89
17. clonazepam	97
18. clonidine	103
19. clorazepate	109
20. clozapine	113
21. cyamemazine	119
22. desipramine	125
23. desvenlafaxine	133
24. diazepam	139
25. donepezil	145
26. dothiepin	151
27. doxepin	157
28. duloxetine	165
29. escitalopram	171
30. estazolam	177
31. eszopiclone	181
32. flumazenil	185
33. flunitrazepam	189
34. fluoxetine	193

35.	flupenthixol	199
36.	fluphenazine	205
37.	flurazepam	211
38.	fluvoxamine	215
39.	gabapentin	221
40.	galantamine	227
41.	guanfacine	233
42.	haloperidol	237
43.	hydroxyzine	243
44.	imipramine	247
45.	isocarboxazid	253
46.	lamotrigine	259
47.	levetiracetam	267
48.	lisdexamfetamine	271
49.	lithium	277
50.	lofepramine	283
51.	loflazepate	289
52.	lorazepam	295
53.	loxapine	301
54.	maprotiline	307
55.	memantine	313
56.	mesoridazine	317
57.	methylphenidate (d)	323
58.	methylphenidate (d,l)	329
59.	midazolam	337
60.	milnacipran	341
61.	mirtazapine	347
62.	moclobemide	353
63.	modafinil	359
64.	molindone	365
65.	naltrexone	369
66.	nefazodone	373
67.	nortriptyline	379
68.	olanzapine	387
69.	oxazepam	393
70.	oxcarbazepine	397
71.	paliperidone	403
72.	paroxetine	409
73.	perospirone	417
74.	perphenazine	421
75.	phenelzine	427

76.	pimozide	433
77.	pipothiazine	439
78.	pregabalin	445
79.	protriptyline	449
80.	quazepam	455
81.	quetiapine	459
82.	ramelteon	465
83.	reboxetine	469
84.	risperidone	475
85.	rivastigmine	483
86.	selegiline	489
87.	sertraline	497
88.	sulpiride	503
89.	temazepam	509
90.	thioridazine	513
91.	thiothixene	519
92.	tiagabine	523
93.	tianeptine	529
94.	topiramate	535
95.	tranylcypromine	541
96.	trazodone	547
97.	triazolam	553
98.	trifluoperazine	557
99.	trimipramine	563
100.	valproate	569
101.	varenicline	575
102.	venlafaxine	579
103.	zaleplon	585
104.	ziprasidone	589
105.	zolpidem	595
106.	zonisamide	599
107.	zopiclone	603
108.	zotepine	607
109.	zuclopenthixol	613
	Index by drug name	619
	Index by use	633
	Index by class	639
	Abbreviations	643
	FDA Use-In-Pregnancy Ratings	645

## Introduction

---

This *Guide* is intended to complement *Stahl's Essential Psychopharmacology*. *Stahl's Essential Psychopharmacology* emphasizes mechanisms of action and how psychotropic drugs work upon receptors and enzymes in the brain. This guide gives practical information on how to use these drugs in clinical practice.

It would be impossible to include all available information about any drug in a single work, and no attempt is made here to be comprehensive. The purpose of this guide is instead to integrate the art of clinical practice with the science of psychopharmacology. That means including only essential facts in order to keep things short. Unfortunately that also means excluding less critical facts as well as extraneous information, which may nevertheless be useful to the reader but would make the book too long and dilute the most important information. In deciding what to include and what to omit, the author has drawn upon common sense and 30 years of clinical experience with patients. He has also consulted with many experienced clinicians and analyzed the evidence from controlled clinical trials and regulatory filings with government agencies.

In order to meet the needs of the clinician and to facilitate future updates of this *Guide*, the opinions of readers are sincerely solicited. Feedback can be emailed to [feedback@neiglobal.com](mailto:feedback@neiglobal.com). Specifically, are the best and most essential psychotropic drugs included here? Do you find any factual errors? Are there agreements or disagreements with any of the opinions expressed here? Are there suggestions for any additional tips or pearls for future editions? Any and all suggestions and comments are welcomed.

All of the selected drugs are presented in the same design format in order to facilitate rapid access to information. Specifically, each drug is broken down into five sections, each designated by a unique color background: ■ therapeutics, ■ side effects, ■ dosing and use, ■ special populations, and ■ the art of psychopharmacology, followed by key references.

**Therapeutics** covers the brand names in major countries; the class of drug; what it is commonly prescribed and approved for by the United States Food and Drug Administration (FDA); how the drug works; how long it takes to work; what to do if it works or if it doesn't work; the best augmenting combinations for partial response or treatment resistance; and the tests (if any) that are required.

**Side effects** explains how the drug causes side effects; gives a list of notable, life-threatening or dangerous side effects; gives a specific rating for weight gain or sedation, and advice about how to handle side effects, including best augmenting agents for side effects.

**Dosing and use** gives the usual dosing range; dosage forms; how to dose and dosing tips; symptoms of overdose; long-term use; if habit forming, how to stop; pharmacokinetics; drug interactions; when not to use and other warnings or precautions.

**Special populations** gives specific information about any possible renal, hepatic, and cardiac impairments, and any precautions to be taken for treating the elderly, children, adolescents, and pregnant and breast-feeding women.

**The art of psychopharmacology** gives the author's opinions on issues such as the potential advantages and disadvantages of any one drug, the primary target symptoms, and clinical pearls to get the best out of a drug.

At the back of the guide are several indices. The first is an index by drug name, giving both generic names (uncapitalized) and trade names (capitalized and followed by the generic name in parentheses). The second is an index of common uses for the generic drugs included in the guide and is organized by disorder/symptom. Agents that are approved by the FDA for a particular use are shown in bold. The third index is organized by drug class, and lists all the agents that fall within each particular class. In addition to these indices there is a list of abbreviations; FDA definitions for the Pregnancy Categories A, B, C, D, and X, and, finally, an index of the icons used in the guide.

Readers are encouraged to consult standard references<sup>1</sup> and comprehensive psychiatry and pharmacology textbooks for more in-depth information. They are also reminded that the art of psychopharmacology section is the author's opinion.

It is strongly advised that readers familiarize themselves with the standard use of these drugs before attempting any of the more exotic uses discussed, such as unusual drug combinations and doses. Reading about both drugs before augmenting one with the other is also strongly recommended. Today's psychopharmacologist should also regularly track blood pressure, weight, and body mass index for most of his or her patients. The dutiful clinician will also check out the drug interactions of non-central-nervous-system (CNS) drugs with those that act in the CNS, including any prescribed by other clinicians.

Certain drugs may be for experts only and might include clozapine, thioridazine, pimozide, nefazodone, mesoridazine, and MAO inhibitors, among others. Off-label uses not approved by the FDA and inadequately studied doses or combinations of drugs may also be for the expert only, who can weigh risks and benefits in the presence of sometimes vague and conflicting evidence. Pregnant or nursing women, or people with two or more psychiatric illnesses, substance abuse, and/or a concomitant medical illness may be suitable patients for the expert only. Controlled substances also require expertise. Use your best judgment as to your level of expertise and realize that we are all learning in this rapidly advancing field. The practice of medicine is often not so much a science as it is an art. It is important to stay within the standards of medical care for the field, and also within your personal comfort zone, while trying to help extremely ill and often difficult patients with medicines than can sometimes transform their lives and relieve their suffering.

Finally, this book is intended to be genuinely helpful for practitioners of psychopharmacology by providing them with the mixture of facts and opinions selected by the author. Ultimately, prescribing choices are the reader's responsibility. Every effort has been made in preparing this book to provide accurate and up-to-date information in accord with accepted standards and practice at the time of publication. Nevertheless, the psychopharmacology field is evolving rapidly and the author and publisher make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. Furthermore, the author and publisher disclaim any responsibility for the continued currency of this information and disclaim all liability for any and all damages, including direct or consequential damages, resulting from the use of information contained in this book. Doctors recommending and patients using these drugs are strongly advised to pay careful attention to, and consult information provided by the manufacturer.

<sup>1</sup>For example, *Physician's Desk Reference* and *Martindale: The Complete Drug Reference*



## List of icons

---



alcohol dependence treatment



alpha 2 agonist



anticonvulsant



antihistamine



benzodiazepine



cholinesterase inhibitor



conventional antipsychotic



dopamine stabilizer



lithium



modafinil (wake-promoter)



monoamine oxidase inhibitor



nefazodone (serotonin antagonist/reuptake inhibitor)



nicotinic partial agonist



*N*-methyl-D-aspartate antagonist



noradrenergic and specific serotonergic antidepressant



norepinephrine and dopamine reuptake inhibitor



sedative-hypnotic



selective norepinephrine reuptake inhibitor



selective serotonin reuptake inhibitor



serotonin-dopamine antagonist



serotonin and norepinephrine reuptake inhibitor



serotonin 1A partial agonist



stimulant



trazodone (serotonin antagonist/reuptake inhibitor)



tricyclic/tetracyclic antidepressant




How the drug works, mechanism of action




Best augmenting agents to add for partial response or treatment-resistance



Life-threatening or dangerous side effects



**Weight Gain:** Degrees of weight gain associated with the drug, with unusual signifying that weight gain has been reported but is not expected; not unusual signifying that weight gain occurs in a significant minority; common signifying that many experience weight gain and/or it can be significant in amount; and problematic signifying that weight gain occurs frequently, can be significant in amount, and may be a health problem in some patients



**Sedation:** Degrees of sedation associated with the drug, with unusual signifying that sedation has been reported but is not expected; not unusual signifying that sedation occurs in a significant minority; common signifying that many experience sedation and/or it can be significant in amount; and problematic signifying that sedation occurs frequently, can be significant in amount, and may be a health problem in some patients



Tips for dosing based on the clinical expertise of the author



Drug interactions that may occur



Warnings and precautions regarding use of the drug



Dosing and other information specific to children and adolescents



Information regarding use of the drug during pregnancy



Clinical pearls of information based on the clinical expertise of the author



Suggested reading